Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27170063 | 1.00 | ADORA2A (0.37) | ADORA2AADORA2B | |
| SCHEMBL12118196 | 0.81 | ADORA2A (0.48) | ADORA2AADORA2B | |
| SCHEMBL29490993 | 0.81 | L3MBTL1 (0.33) | ADORA2AADORA2B | |
| SCHEMBL30791764 | 0.81 | NMT1 (0.37) | ADORA2AADORA2B | |
| SCHEMBL24252947 | 0.81 | NMT1 (0.37) | ADORA2AADORA2B | |
| SCHEMBL25429967 | 0.81 | L3MBTL1 (0.33) | ADORA2AADORA2B | |
| SCHEMBL31393091 | 0.77 | LMNA (0.34) | ADORA2AADORA2B | |
| SCHEMBL18299177 | 0.76 | KDM4E (0.38) | ADORA2AADORA2B | |
| SCHEMBL29985736 | 0.75 | ADORA2A (0.34) | ADORA2AADORA2B | |
| SCHEMBL31437641 | 0.74 | MAPT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHROEDINGER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715642-A | Heterocyclic compounds and methods of use | 薛定谔公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| WO-2022251497-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | ADORA2A 4444/4885ADORA2B 4621/4885 |
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | ADORA2A 4664/4885ADORA2B 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.